Jefferies, Piper adjust ResMed targets

• Deutsche isn't the only firm rethinking its price target on ResMed (RMD -11.6%) today, after the company turned in FQ1 numbers that disappointed Wall Street.
• Jefferies is out increasing its target to $46 from $40.
• Piper cuts target to $57 from $59.